Another preclinical study utilized an ADC, linking E7766 to an antibody against prostate-specific membrane antigen (PSMA) to target PSMA-expressing prostate cancer cells, delivering the drug E7766 with high specificity to the tumor. Here, FOLH1 is linked to neoplasm.